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1. Introduction 
The nerve growth factor NGF belongs to the neurotrophin family and was described for the 
first time more than fifty years ago by Rita Levi-Montalcini and collaborators (Levi-
Montalcini et al., 1995; Levi-Montalcini & Hamburger, 1951), who showed its major role in 
neuronal growth and survival. NGF effects are mediated by activation of two receptor types: 
the low-affinity p75 receptor for neurotrophins (p75NTR) and the high-affinity tropomyosin-
related kinase A (TrkA) receptor (Freund-Michel & Frossard, 2008a). The p75NTR receptor 
belongs to the death receptor family and its activation by NGF at nanomolar concentrations 
leads either to pro- or anti-apoptotic signalling pathways. The p75NTR receptor is not 
selective for NGF as it can also bind pro-neurotrophins and the other neurotrophins at the 
same nanomolar concentrations (Chao, 2003). Inversely, the TrkA receptor is selective for 
NGF and belongs to the tyrosine-kinase receptor family. Its activation by NGF at picomolar 
concentrations activates signalling pathways inducing cell proliferation, differentiation and 
survival in particular through activation of phosphatidylinositol-3 kinase (PI3K), small 
protein G Ras, phospholipase C (PLC) and mitogen-activated protein kinases (MAPK) 
(Freund-Michel & Frossard, 2008a). 
The role of NGF in neuronal growth and survival has been widely studied and led to 
consider NGF as a promising therapeutic target in several pathologies of the nervous 
system, in particular neurodegenerative diseases (Prakash et al., 2010). In addition, many 
studies have suggested that NGF also plays the role of an inflammatory mediator, in 
particular in the lung (Freund-Michel & Frossard, 2008a). Indeed, numerous sources of 
NGF have been described in the lung, including infiltrated inflammatory cells, sensory 
nerves, and many lung structural cells such as fibroblasts, epithelial, endothelial, and 
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airway or pulmonary vascular smooth muscle cells (Ricci et al., 2004b). These cells have 
been shown to release more NGF in inflammatory conditions, and may thus participate in 
increased NGF levels observed in pulmonary inflammatory diseases. In parallel, many 
studies have shown an active role of NGF in pulmonary inflammation, airway sensory 
nerve plasticity, airway and vascular hyperreactivity and remodelling (Freund-Michel & 
Frossard, 2008a). Most of these NGF effects occur through activation of the TrkA receptor, 
thus highlighting the pivotal role played by this receptor in pulmonary inflammatory 
diseases.  
The aim of the present chapter is to describe the role of the TrkA receptor activated by NGF 
in pulmonary inflammatory diseases. We will first present the TrkA receptor by describing 
its discovery, its structure and activity as well as its major signalling pathways. We will then 
focus on the TrkA receptor in the lung, by describing its pulmonary expression and review 
its involvement in NGF-mediated effects in the lung. We will describe in particular how the 
TrkA receptor participates to NGF-induced inflammation, airway and vascular 
hyperreactivity and remodelling in the lung, focusing on two major pulmonary diseases: 
asthma and pulmonary hypertension. 
2. Presentation of the TrkA receptor 
The TrkA receptor belongs to the Trk receptor family, together with TrkB and TrkC 
receptors. Each Trk receptor binds with a picomolar affinity to a preferred ligand: NGF for 
TrkA, BDNF (brain-derived neurotrophic factor) and NT-4/5 (neurotrophin-4/5) for TrkB, 
and NT-3 (neurotrophin-3) for TrkC (Chao, 2003). However, some crosstalks have been 
described, in particular for NT-3 being able to bind TrkA and TrkB receptors but at higher 
concentrations (Ryden & Ibanez, 1996). 
2.1 Discovery of the TrkA receptor 
A proto-oncogene was identified in 1986 by Martin-Zanca and co-workers in human colon 
carcinomas (Martin-Zanca et al., 1986). This proto-oncogene, resulting from fusion between 
genes encoding for a tyrosine-kinase domain and a non muscular tropomyosin, was named 
NTRK or trk for « tropomyosin-related kinase ». Three isoforms were identified and named 
NTRK1 (or TRKA), NTRK2 (or TRKB) and NTRK3 (or TRKC), with proteins encoded by 
these genes named Trk (TrkA, TrkB and TrkC) (Martin-Zanca et al., 1986). Expression of Trk 
proteins was later also detected in thyroid carcinomas and other cancers such as melanomas 
or breast cancers, as well as in non cancer tissues, in particular in the nervous system (Greco 
et al., 1997). In 1991, the TrkA protein was identified as the high affinity receptor for NGF 
(Kaplan et al., 1991a; Klein et al., 1991). 
2.2 Structure of the TrkA receptor 
The human TrkA receptor is encoded by a gene of 23kb located on chromosome 1q21-q22 
(Weier et al., 1995). This gene contains 16 introns of 70bp to 3.3kb and 17 exons of 18 to 
394bp (Indo et al., 1997), with the 9 first exons encoding for the extracellular part of the 
receptor (Metsis, 2001). The TrkA protein contains 790 amino acids with a molecular weight 
of 140 kDa (Meakin & Shooter, 1992), and is composed of an intracellular domain containing 
a tyrosine-kinase intrinsic activity, a unique transmembrane helix, and an extracellular 
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domain dedicated to NGF binding (Wiesmann & de Vos, 2001). This extracellular domain is 
highly glycosylated, which is essential for activation of TrkA signalling pathways (Friedman 
& Greene, 1999). 
Alternative splicing leads to several isoforms of the TrkA receptor. TrkA I and TrkA II 
splice variants differ only in the presence or absence of a 6 amino acid sequence. 
However, even if TrkA II expression is restricted to the nervous system, whereas TrkA I is 
more ubiquitously expressed (Clary & Reichardt, 1994), no differences in NGF binding or 
in TrkA function have been identified between these two isoforms (Barker et al., 1993). 
More recently, a novel hypoxia-regulated TrkA III splice variant has also been described: 
this isoform is expressed on internal membranes (Tacconelli et al., 2005) and exhibits 
oncogenic activity (Farina et al., 2009). Finally, a metalloproteinase-dependent cleavage of 
TrkA extracellular domain has been described, with release of a soluble fragment whose 
function remains unknown (Cabrera et al., 1996). In parallel, this cleavage induces 
activation of TrkA intracellular kinase domain, thus providing a TrkA NGF-independent 
activation, which may contribute to TrkA-dependent effects in vivo (Diaz-Rodriguez et al., 
1999).  
2.3 Activation and signalling pathways of the TrkA receptor 
As classically described for other tyrosine-kinase receptors, NGF binds to the 
extracellular domain of the TrkA receptor and induces its dimerization thereby 
activating its intracellular tyrosine kinase domain (Kaplan et al., 1991b). Each kinase 
domain induces phosphorylation of three tyrosine residues (Y670, Y674 and Y675) on the 
contralateral kinase domain (Mitra, 1991), thus leading to enhancement of kinase activity 
and further phosphorylation of three other tyrosine residues outside the kinase domain 
(Y490, Y751 and Y785) (Stephens et al., 1994). These newly phosphorylated tyrosine 
residues are then recognized by proteins through their SH2 (Src homology domain 2) 
domains. The adapter protein Shc (Src homology 2-containing protein) interacts with the 
phosphorylated Y490 residue, phosphatidyl-inositol 3-kinase (PI3K) interacts with the 
phosphorylated Y751 residue, and phospholipase C (PLC) interacts with the 
phosphorylated Y785 residue, thereby initiating three main signalling pathways that 
have been widely studied in particular in neuronal cells (Skaper, 2008). However, some 
recent studies also show activation of these TrkA signalling pathways in non neuronal 
cells, and in particular in the airways (for reviews: Freund-Michel & Frossard, 2008a; 
Prakash et al., 2010). 
2.3.1 Ras/Raf pathway 
Shc intracellular binding to the TrkA receptor leads to phosphorylation of its tyrosine 
residues and further recognition by the adapter protein Grb-2 (growth factor receptor bound 
protein-2) through SH3 (Src homology domain 3) domains. Grb-2 then binds to the factor 
sos (factor son of sevenless) to induce recruitment of the small G protein Ras to the cell 
membrane and its activation (Segal & Greenberg, 1996). This translocation to the cell 
membrane enables Ras-induced activation of the Raf kinase and therefore phosphorylation 
of Raf and activation of the MAPK (mitogen-activated protein kinase) ERK1/2 
(extracellular-regulated protein kinase 1/2), leading to activation of survival mechanisms 
and proliferation (Freund-Michel et al., 2006). Concomitant activation of Rap1, another small 
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G protein, can potentiate Ras activation and enhance activation of the ERK1/2 pathway 
(York et al., 2000).  
2.3.2 PI3K pathway 
PI3K intracellular binding to the TrkA receptor leads to its phosphorylation and activation. 
PI3K then induces synthesis of phosphatidyl-inositol 3,4-bisphosphate that recruits PDK-1 
(phosphoinositide-dependent kinase-1) to the cell membrane and induces activation of PKB 
(protein-kinase B, also called Akt) (Ashcroft et al., 1999). PKB then leads to activation of 
gene transcription, either through activation of the small G protein Rac and the MAPK 
pathway (Kita et al., 1998; Yamaguchi et al., 2001), or through activation of the atypical PKC 
zeta in a MAPK-independent manner (Wooten et al., 1994). In addition, PKB can lead to 
activation of proteins belonging to the IAP (inhibitors of apoptosis) family that are involved 
in cell survival (Wiese et al., 1999). Finally, a Ras-dependent activation of PI3K has also been 
described, through direct interaction between Ras and PI3K in a complex also containing the 
adapter protein Gab-1 (Grb2-associated binder-1) after activation of Shc and Grb-2 
(Holgado-Madruga et al., 1997; Korhonen et al., 1999). 
2.3.3 PLC/PKC pathway 
PLC is activated by its interaction with the TrkA receptor and its phosphorylation by TrkA 
intrinsic kinase domains. PLC then induces cleavage of phosphatidyl inositol 4,5-
bisphosphate into inositol trisphosphate (IP3) and diacylglycerol (DAG). DAG activates 
protein-kinase C (PKC) to activate the MAPK pathway, with in particular activation of JNK 
(c-jun N-terminal kinase) and p38 (Patapoutian & Reichardt, 2001). IP3 binds to its receptor 
localized on the endoplasmic reticulum and induces calcium release into the cell cytoplasm, 
thus contributing to PKC activation (Obermeier et al., 1993).  
2.4 Transactivation of the TrkA receptor by G protein-coupled receptors 
Neurotrophin-independent activation of Trk receptors, and in particular of the TrkA 
receptor, has been evidenced in rat neuronal cells after adenosine treatment (Lee & Chao, 
2001). Activation of the adenosine A2A receptor, a G protein-coupled receptor (GPCR), 
induces activation of a kinase belonging to the Src family that is then able to phosphorylate 
the TrkA receptor and activate the PI3K/PKB pathway (Lee & Chao, 2001; Lee et al., 2002a). 
This effect has also been evidenced with another GPCR agonist, the pituitary adenylate 
cyclase-activating peptide (PACAP), being able to induce TrkA transactivation and specific 
activation of the PI3K/PKB pathway in absence of NGF (Lee et al., 2002b). Since 
neuroprotective effects of adenosine and PACAP had been previously demonstrated, it has 
been suggested that this TrkA transactivation mechanism may contribute to these 
neuroprotective effects through activation of PI3K/PKB (Lee et al., 2002b). However more 
recent studies suggested that this TrkA transactivation mechanism occurred on newly 
synthesized TrkA receptors that were not already expressed at the cell membrane 
(Rajagopal et al., 2004). 
2.5 Trafficking of the TrkA receptor 
NGF activation of the TrkA receptor expressed on neurons can activate signalling pathways 
close to the nucleus through a specific mechanism called retrograde transport (Heerssen & 
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Segal, 2002). Once activated by NGF, the TrkA receptor is internalized, mainly through 
activation of three mechanisms:  clathrine-dependent internalization, caveolae-dependent 
internalization, or macroendocytosis (Philippidou et al., 2011; Zweifel et al., 2005). All these 
mechanisms are involved in TrkA internalization and depend i) on the cell type studied, ii) 
on the concentration of NGF, and iii) on the amplitude of the signal generated by TrkA 
activation (Zweifel et al., 2005). Once internalized, only a few number of TrkA receptors are 
transported close to the nucleus, using early endosomes characterized by expression of the 
small G protein Rab5 and its effector EEA1 (Early endosome antigen 1) (Delcroix et al., 
2003). TrkA retrograde transport is dependent upon activation of the PI3K-PKB pathway 
(Delcroix et al., 2003; Kuruvilla et al., 2000; York et al., 2000). Most of internalized TrkA 
receptors are either degraded through targeting to lysosomes (Jullien et al., 2002; Saxena et 
al., 2005) or to the proteasome after ubuquitination (Georgieva et al., 2011; Takahashi et al., 
2011), or recycled at the cell membrane (Chen et al., 2005). 
3. TrkA expression in the lung 
Neurotrophin expression was first described in the central and peripheral nervous systems, 
participating to nerve growth and survival through activation of Trk and p75NTR receptors. 
However, neurotrophins and their receptors were later also described in a variety of non-
neuronal tissues, and in particular in the lung (Lomen-Hoerth & Shooter, 1995). 
3.1 In vitro studies 
3.1.1 Inflammatory cells 
NGF expression, which was first reported in T lymphocytes (Ehrhard et al., 1993a), was later 
also described in a variety of inflammatory cells including B lymphocytes (Torcia et al., 
1996), mast cells (Leon et al., 1994), eosinophils (Solomon et al., 1998) and macrophages 
(Ricci et al., 2000b). Expression of the TrkA receptor was shown on mast cells (Tam et al., 
1997), Th2 lymphocytes (Ehrhard et al., 1993a; Lambiase et al., 1997), B lymphocytes (Torcia 
et al., 1996), eosinophils (Hahn et al., 2006; Nassenstein et al., 2003; Noga et al., 2002), 
monocytes and macrophages (Ehrhard et al., 1993b; Otten et al., 1994), and basophils (Burgi 
et al., 1996). 
3.1.2 Airway structural cells 
Many airway structural cells such as fibroblasts (Antonelli et al., 2005; Olgart & Frossard, 
2001), epithelial cells (Fox et al., 2001; Pons et al., 2001), airway smooth muscle cells (Freund 
et al., 2002), pulmonary endothelial and vascular smooth muscle cells (Freund-Michel et al., 
2009) are sources of NGF (Fig. 1). Investigation of TrkA expression on these cells showed 
TrkA expression in particular on pulmonary fibroblasts (Micera et al., 2001), airway smooth 
muscle cells (Dagnell et al., 2007; Freund-Michel et al., 2006; Freund-Michel & Frossard, 
2008b), airway epithelial cells (Othumpangat et al., 2009), and pulmonary endothelial and 
vascular smooth muscle cells (Freund-Michel et al., 2010) (Fig. 1).  
3.2 In vivo studies 
Expression of TrkA mRNA was initially evidenced in rat and human lung homogenates 
(Barbacid et al., 1991; Lomen-Hoerth &  Shooter, 1995). Expression of TrkA protein was then 
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shown by immunohistochemistry in isolated human alveolar macrophages (Ricci et al., 
2000b), in isolated extrapulmonary arteries (Ricci et al., 2000a), and was later also evidenced 
on human airway and vascular smooth muscles, on alveolar cells, on airway sensory nerves, 
as well as on infiltrated inflammatory cells, in particular macrophages, mast cells and 
lymphocytes (Kassel et al., 2001; Olgart Hoglund et al., 2002; Ricci et al., 2004b). Similar TrkA 
expression was shown in the mouse lung (Hikawa et al., 2002; Nassenstein et al., 2006). 
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Fig. 1. Expression of NGF and its receptors in human pulmonary vascular cells 
A) NGF protein levels (pg/ml) secreted after 24h by human pulmonary arterial smooth 
muscle cells (hPASMC) or human pulmonary arterial endothelial cells (hPAEC) in primary 
culture were assessed by ELISA in the culture cell supernatant. Data are means ± S.E.M. of 
n=3 experiments performed in triplicates with cells from two different donors. B) TrkA and 
p75NTR proteins were detected by Western blotting in cultured hPASMC or hPAEC from 
two different donors (D1 and D2), with rabbit polyclonal anti-human TrkA or p75NTR 
antibodies as specific protein bands of 140 and 75 kDa respectively. β-Actin probed in the 
same blots was used to control for protein loading. 
4. NGF effects in the lung mediated by activation of the TrkA receptor 
NGF is able to stimulate inflammatory cells infiltrated in the bronchial mucosa, promoting 
in particular their activation and survival in the airways (Freund-Michel & Frossard, 2008a). 
NGF also displays its role of growth factor on airway nerves, in particular on sensory 
airway nerves (Hoyle et al., 1998), and is able to stimulate other airway structural cells such 
as pulmonary fibroblasts or airway smooth muscle cells (Freund-Michel & Frossard, 2008a). 
Some of these effects involve activation of the TrkA receptor expressed on these cells  
(Fig. 2). 
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Fig. 2. NGF effects in the lung mediated via activation of the TrkA receptor 
NGF-induced activation of the TrkA receptor participates to attraction and activation of 
inflammatory cells in the lung and may therefore contribute to lung inflammation. The TrkA 
receptor is also expressed on lung structural cells and participates to NGF-induced effects 
that may contribute to altered reactivity and remodelling processes existing in pulmonary 
inflammatory diseases. 
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4.1 TrkA and inflammatory cells 
4.1.1 Mast cells 
In vitro, activation of the TrkA receptor by NGF induces granule formation in immature 
mast cells and therefore contributes to their differentiation (Kim et al., 2008). In addition, 
NGF is a chemotactic factor for mast cells through both MAPK and PI3K signalling 
pathways following TrkA activation (Sawada et al., 2000).  TrkA activation is also 
involved in NGF-induced degranulation of mast cells and mediators release such as for 
example chemokines (Ahamed et al., 2004), or serotonin (Kawamoto et al., 2002). Finally, 
NGF acts as a key factor to promote mast cell survival through TrkA-induced suppression 
of apoptosis (Kawamoto et al., 1995). In vivo, a correlation between NGF levels in 
bronchoalveolar lavage (BAL) fluids and the number of mast cells infiltrated in the 
bronchial mucosa has been evidenced in asthmatic patients after allergenic challenge 
(Kassel et al., 2001). Expression of TrkA receptors on these mast cells therefore suggests a 
role for this receptor in NGF-induced attraction and survival of these cells in the lung in 
vivo (Kassel et al., 2001).  
4.1.2 Basophils 
In vitro, NGF potentiates mediator release from human basophils as well as primes the cells 
to produce leukotriene C4, and these effects are TrkA-dependent (Burgi et al., 1996). NGF 
can also modulate IgE-mediated responses in human basophils, and these effects are 
enhanced on cells from allergic subjects (Sin et al., 2001). However, flow cytometry studies 
revealed no significant differences in TrkA receptor expression on basophils in this study 
(Sin et al., 2001). 
4.1.3 T and B cells 
Although various effects of NGF have been described on T lymphocytes, few studies have 
investigated the role of the TrkA receptor in these effects. Only one study by Ehrhard and 
co-workers clearly demonstrates involvement of the TrkA receptor in NGF-induced 
activation of T lymphocytes in vitro (Ehrhard et al., 1994). In vivo, NGF effects on T 
lymphocytes remain controversial, since two studies conducted in a mouse model of asthma 
failed to show NGF-related effects on T cells (Braun et al., 1998; Path et al., 2002). However, 
in a transgenic mouse tissue-specifically overexpressing NGF in the lung, increased 
numbers of T lymphocytes have been shown in the lung after allergenic challenge (Quarcoo 
et al., 2004). The role of NGF and its TrkA receptor on T lymphocytes in pulmonary 
inflammatory diseases needs therefore to be further clarified in vivo. 
NGF has been shown to induce proliferation of B lymphocytes in vitro, and this effect occurs 
through activation of the TrkA receptor and its signalling pathways involving PLC, PI3K 
and MAPK (Melamed et al., 1996). NGF-induced activation of the TrkA receptor also 
participates to B cell survival through  PI3K-dependent activation of PKC zeta (Kronfeld et 
al., 2002). In vivo, in mice lacking TrkA in non-neuronal tissues, all major immune system 
cell populations were present in normal numbers and distributions, excepted for B 
lymphocytes, demonstrating that endogenous NGF modulates B cell development through 
activation of the TrkA receptor (Coppola et al., 2004). Moreover, during allergic airway 
inflammation in the mouse in vivo, NGF contributes to B cell differentiation into plasma cells 
and activates the TrkA receptor to enhance plasma cell survival and production of 
immunoglobulins E (Abram et al., 2009).  
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4.1.4 Eosinophils 
In vitro, eosinophil degranulation is promoted by NGF-induced activation of the TrkA 
receptor, inducing release of inflammatory mediators such as interleukin-4 (Noga et al., 
2002). In vitro NGF treatment of eosinophils from patients with allergic bronchial asthma 
increases viability of these cells, and this effect is correlated to increased expression of the 
TrkA receptor on eosinophils (Nassenstein et al., 2003). In addition, coculture of lung 
eosinophils with airway epithelial cells resulted in enhanced epithelial neurotrophin 
production, as well as in prolonged survival of eosinophils (Hahn et al., 2006). Complete 
inhibition of eosinophil survival in the presence of the TrkA kinase inhibitor K252a 
confirmed the important role of the TrkA receptor in eosinophil survival (Hahn et al., 2006).  
4.1.5 Monocytes / macrophages 
NGF induces TrkA activation in monocytes in vitro to trigger a respiratory burst, the major 
component of monocyte cytotoxic activity (Ehrhard et al., 1993b). Activation of the TrkA 
receptor by NGF also promotes monocytes survival (la Sala et al., 2000). TrkA transactivation 
mechanisms with GPCR ligands, recently evidenced in monocytes, contribute to pro-
inflammatory activities such as for example synthesis of reactive oxygen species (El Zein et al., 
2007, 2010). Expression of the TrkA receptor was shown to decrease during in vitro 
differentiation of monocytes to macrophages, suggesting a maturation-dependent regulation 
of TrkA expression in these cells (Ehrhard et al., 1993b). 
NGF was reported to activate macrophages in vitro in the process of inflammatory and 
immune actions, inducing phagocytosis, parasite killing, and production of inflammatory 
cytokines in a TrkA dependent-manner (Barouch et al., 2001; Susaki et al., 1996). In vivo, TrkA 
expression was reported on human alveolar macrophages (Ricci et al., 2004b; Ricci et al., 
2000b), and the TrkA receptor and its binding protein SH2-B participate to activation of 
alveolar macrophages in vivo in a guinea pig model of asthma (Li et al., 2009). 
4.1.6 Neutrophils 
In a murine model of rhinitis induced by toluene diisocyanate exposure, a massive increased 
number of neutrophils in the nasal mucosa correlates to increased levels of NGF (Wilfong & 
Dey, 2004 & 2005). Neutrophil infiltration was inhibited after in vivo pre-treatment with the 
TrkA kinase inhibitor K252a, thus showing the important role of the TrkA receptor on 
neutrophil attraction in the nasal mucosa (Wilfong & Dey, 2004). 
4.2 TrkA and airway structural cells 
A role for the TrkA receptor has been evidenced in NGF-induced effects on airway sensory 
nerves. In particular, NGF induces release of neuropeptides such as substance P by airway 
neurons, and this effect is TrkA-dependent (de Vries et al., 2006; Dinh et al., 2004). A similar 
effect has been reported in nasal sensory neurons (Wilfong & Dey, 2004). NGF induces 
proliferation of airway smooth muscle cells through activation of the TrkA receptor 
(Freund-Michel et al., 2006). We also showed that NGF multiple stimulation of these cells 
induce internalization and degradation of the TrkA receptor followed by upregulated re-
synthesis of functional TrkA receptors and increased proliferative effect (Freund-Michel & 
Frossard, 2008b). In ongoing studies, we have recently found that NGF induces proliferation 
and migration of human pulmonary endothelial and vascular smooth muscle cells in vitro, 
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and that these effects are inhibited by pre-treatment with the TrkA kinase inhibitor K252a, 
thus suggesting a role for the TrkA receptor in these NGF-mediated effects (Freund-Michel 
et al., 2009) (Fig. 3). 
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Fig. 3. Involvement of the TrkA receptor in NGF-induced effects on human pulmonary 
vascular cells. 
Effect of NGF (0.1, 10 or 100 ng/ml) after 24h on A) human pulmonary arterial smooth muscle 
cells (hPASMC) or B) human pulmonary arterial endothelial cells (hPAEC) in primary culture. 
Cell proliferation was assessed by the BrdU technique and cell migration was evaluated by the 
Transwell assay. Data are presented as the maximal percentage of increased proliferation or 
migration compared to untreated control cells. NGF effect was evaluated in the presence or 
absence of the TrkA kinase inhibitor K252a (100nM, 30min pre-treatment followed by 24h 
concomitant treatment with NGF). ***: P<0.001 versus NGF alone with n=5 independent 
experiments performed in triplicates with cells from two different donors. 
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5. Role of the TrkA receptor in pulmonary inflammatory diseases 
Circulating NGF levels are increased in human allergic and inflammatory diseases (Bonini 
et al., 1996). A local increase in NGF secretion has also been evidenced in BAL fluid from 
asthmatic patients (Kassel et al., 2001; Olgart Hoglund et al., 2002). In addition, our ongoing 
studies show that pulmonary arteries from patients suffering from pulmonary hypertension 
secondary to chronic obstructive pulmonary diseases (COPD) secrete more NGF than 
pulmonary arteries from control donors (Freund-Michel et al., 2010). Asthma and 
pulmonary hypertension share in common three major features occurring either in airways 
or in pulmonary arteries: inflammation, tissue hyperreactivity and remodelling (Barnes, 
2010; Broide et al., 2011; Hassoun et al., 2009; Humbert, 2010).  Several in vitro and in vivo 
studies suggest that NGF may play a role in these three physiopathological mechanisms, in 
particular through activation of the TrkA receptor (Fig. 4). 
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Fig. 4. Potential role of the TrkA receptor in asthma and pulmonary hypertension 
In vitro and in vivo studies suggest that activation of the TrkA receptor by NGF contributes 
to inflammation as well as tissue remodelling and altered reactivity, three features occurring 
in particular in airways and in pulmonary arteries and playing a major role in the 
physiopathology of asthma and pulmonary hypertension. 
5.1 NGF, TrkA and inflammation 
5.1.1 Asthma 
In a mouse model of asthma, NGF inhibition induced by blocking antibodies administered 
in vivo decreases airway inflammation (Braun et al., 1998; Path et al., 2002). On the contrary, 
allergen sensitization and challenge in a transgenic mouse tissue specifically overexpressing 
NGF in the lung displays greater airway inflammation (Path et al., 2002; Quarcoo et al., 
2004). In vivo administration of a pan-Trk receptor decoy in a mouse model of asthma 
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reduces interleukin-(IL-)4 and IL-5 cytokine levels (Nassenstein et al., 2006). Substance P is 
one of the neuropeptides released by airway sensory nerves that participates to neurogenic 
inflammation in asthma (Quarcoo et al., 2004). In vivo treatment with the TrkA kinase 
inhibitor K252a prevents the increase in substance P observed in a guinea pig model of 
asthma (de Vries et al., 2006). In vivo pre-treatment with TrkA blocking antibodies decreases 
IL-1 and IL-4 levels in the BAL fluid after allergen sensitization and challenge in the guinea 
pig (Li et al., 2009). Similar results are observed with TrkA blocking antibodies in a mouse 
model of asthma (Ni et al., 2010). Altogether, these results show a major role of NGF in 
airway inflammation through activation of its TrkA receptor. 
5.1.2 Pulmonary hypertension 
We recently showed that NGF stimulates secretion of inflammatory cytokines such as IL-1 
and tumor necrosis factor- from rat and human pulmonary arteries (Freund-Michel et al., 
2010). Moreover, in vivo treatment with anti-NGF blocking antibodies in animal models of 
pulmonary hypertension prevents the increased secretion of these inflammatory cytokines 
from diseased pulmonary arteries (Freund-Michel et al., unpublished data). Contribution of 
the TrkA receptor in these mechanisms remains to be determined, but our preliminary data 
support a role for NGF in the inflammatory mechanisms associated to pulmonary 
hypertension. 
5.2 NGF, TrkA and tissue hyperresponsiveness  
5.2.1 Asthma 
A role for NGF was reported in airway hyperresponsiveness (AHR) associated to asthma, 
since pre-treatment with anti-NGF blocking antibodies reduces AHR in various animal 
models of asthma (Braun et al., 1998; de Vries et al., 2006; Glaab et al., 2003). In addition, 
AHR is observed after in vitro NGF pre-treatment of guinea pig (de Vries et al., 2001), ferret 
(Wu & Dey, 2006) or human bronchi (Frossard et al., 2005). AHR is reduced in vivo after 
administration of a pan-Trk receptor decoy in a mouse model of asthma (Nassenstein et al., 
2006), or of the TrkA kinase inhibitor K252a in a guinea pig model of asthma (de Vries et al., 
2006), thus showing involvement of the TrkA receptor in NGF-induced AHR. 
5.2.2 Pulmonary hypertension 
In the systemic circulation, neurotrophins play a role in the control of vascular tone 
(Caporali & Emanueli, 2009), and a role for NGF has been suggested in systemic arterial 
hypertension (Sherer et al., 1998). Neurotrophins and their receptors are expressed on 
pulmonary arteries (Ricci et al., 2000a), and their expression is increased in the lung of 
spontaneously hypertensive rats (Ricci et al., 2004a). A role for neurotrophins in the control 
of the pulmonary arterial tone was recently proposed, through activation of the p75NTR 
receptor (Xu et al., 2008). BDNF and NT-3 induce relaxation of porcine pulmonary arterial 
rings, through activation of the endothelial nitric oxide synthase (Meuchel et al., 2011). 
Suppression of TrkB or TrkC expression via siRNA as well as functional blockade of p75NTR 
suggest a role of both Trk and p75NTR receptors in these effects (Meuchel et al., 2011). In our 
ongoing studies in rat or human pulmonary arteries, we show that NGF does not induce rat 
or human pulmonary arterial contraction or relaxation by itself. However, NGF pre-
treatment induces pulmonary arterial hyperresponsiveness to contractile agents such as 
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phenylephrine or prostaglandin F2 (Freund-Michel et al., 2010). Our preliminary data 
suggest that this effect may be due in part to activation of the TrkA receptors and increased 
intracellular calcium concentrations. These mechanisms are in accordance with the 
preliminary data recently described for BDNF and NT-3 by Prakash and co-workers 
(Prakash et al., 2010). Altogether, these results therefore suggest that neurotrophins, through 
activation of both Trk and p75NTR receptors, participate in both endothelial dysfunction and 
smooth muscle hyperreactivity observed in pulmonary hypertension. 
5.3 NGF, TrkA and tissue remodelling 
5.3.1 Asthma 
Airway remodelling in asthma is characterized by a sub-epithelial fibrosis with an increased 
proliferation of fibroblasts and a thickening of the basement membrane, 
hypervascularisation, sensory hyperinnervation, oedema, and hypertrophy and hyperplasia 
of the smooth muscle layer (Bara et al., 2010). In vitro, NGF activates the TrkA receptor to 
induce migration of pulmonary fibroblasts (Kohyama et al., 2002) and regulation of 
extracellular matrix synthesis (Khan et al., 2002; Takahashi et al., 2000). These results 
therefore suggest a role for the TrkA receptor in NGF-induced airway sub-epithelial fibrosis 
in vivo (Hoyle et al., 1998). We also reported that NGF induces proliferation of the airway 
smooth muscle through activation of the TrkA receptor and may therefore participate to 
hyperplasia of the smooth muscle layer in vivo (Freund-Michel et al., 2006). Activation of the 
TrkA receptor by NGF also stimulates vascular cells from other origins than the lung to 
induce migration and proliferation of endothelial cells (Cantarella et al., 2002; Dolle et al., 
2005; Lecht et al.,2010 ; Rahbek et al., 2005) as well as migration of vascular smooth muscle 
cells (Donovan et al., 1995; Kraemer et al., 1999). In addition, NGF stimulates angiogenesis in 
vivo through activation of the TrkA receptor (Cantarella et al., 2002; Caporali & Emanueli, 
2009). NGF is also able to stimulate synthesis of angiogenic factors such as vascular 
endothelial growth factor (VEGF) from various cells through activation of its TrkA receptor 
(Nakamura et al., 2011). Altogether, these results suggest that activation of the TrkA 
receptor participates to NGF-mediated hypervascularisation in the lung (Hoyle et al., 1998). 
5.3.2 Pulmonary hypertension 
Vascular remodelling in pulmonary hypertension is characterized by increased 
proliferation, decreased apoptosis and increased migration of pulmonary vascular cells 
(Humbert et al., 2004). NGF-induced activation of the TrkA receptor contributes to 
migration and proliferation of vascular cells from other origins than the lung and stimulates 
angiogenesis (see paragraph above). Our recent results show that NGF induces proliferation 
and migration of pulmonary vascular cells through activation of the TrkA receptor (see 
paragraph 4.2 and Fig. 3) (Freund-Michel et al., 2010). Therefore, our findings support a role 
for NGF and its TrkA receptor in pulmonary vascular remodelling in this disease. 
6. Therapeutic perspectives and conclusion 
In regard of the different results presented in this review, NGF seems to play a major role in 
altered inflammatory, remodelling and reactivity processes occurring in pulmonary 
inflammatory diseases such as asthma or pulmonary hypertension. The TrkA receptor is 
involved in many NGF effects in the lung and targeting NGF or its TrkA receptor may be a 
new therapeutic perspective in these diseases.  
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Outside the lung, blockade of NGF is of therapeutic interest in other areas, in particular in 
pain therapy (Hefti et al., 2006). Humanized monoclonal antibodies against NGF or against 
TrkA, as well as small molecules acting as TrkA antagonists or as TrkA kinase inhibitors 
have been developed and are currently under investigation (Ma et al., 2010; Martin et al., 
2011; McNamee et al., 2010; Ueda et al., 2010; Watson et al., 2008) (Fig. 5). In particular, 
tanezumab, a recombinant humanized monoclonal antibody against NGF, has been recently 
tested in clinical trials in osteoarthritic pain and chronic lower back pain and demonstrated 
good efficacy (Cattaneo, 2010; Lane et al., 2010).  Such strategies may be applied in the near 
future to target NGF or its receptors in pulmonary inflammatory diseases such as asthma or 
pulmonary hypertension in which NGF and its TrkA receptor play an important role. 
 
TrkA
NGF
Anti-NGF blocking antibodies
 TrkAd5
Watson et al., 2008; McNamee et al., 2010
Anti-TrkA blocking antibodies
 TrkA antagonists
Watson et al., 2008
 Kinase inhibitors
 Inhibitory peptides
Martin et al., 2011; Ueda et al., 2010; 
Ma et al., 2010
 
Fig. 5. Potential therapeutic strategies to target the TrkA receptor in pulmonary 
inflammatory diseases. 
To trap circulating NGF and prevent its binding to the TrkA receptor, tools such as anti-
NGF blocking antibodies or soluble chimeric TrkA receptors have been developed. Other 
tools have been developed to target the TrkA receptor itself, either by blocking NGF binding 
to its extracellular part with antagonists or anti-TrkA antibodies, or by blocking TrkA kinase 
activity with kinase inhibitors. 
7. References 
Abram, M., Wegmann, M., Fokuhl, V., Sonar, S., Luger, E.O., Kerzel, S., Radbruch, A., Renz, 
H. & Zemlin, M. (2009). Nerve growth factor and neurotrophin-3 mediate survival 
of pulmonary plasma cells during the allergic airway inflammation. Journal of 
Immunology, Vol.182, No.8, pp. 4705-4712, ISSN 0022-1767. 
www.intechopen.com
 
Expression and Role of the TrkA Receptor in Pulmonary Inflammatory Diseases 
 
89 
Ahamed, J., Venkatesha, R.T., Thangam, E.B. & Ali, H. (2004). C3a enhances nerve growth 
factor-induced NFAT activation and chemokine production in a human mast cell 
line, HMC-1. Journal of Immunology, Vol.172, No.11, pp. 6961-6968, ISSN 0022-1767. 
Antonelli, A., Lapucci, G., Vigneti, E., Bonini, S. & Aloe, L. (2005). Human lung fibroblast 
response to NGF, IL-1beta, and dexamethsone. Lung, Vol.183, No.5, pp. 337-351, 
ISSN 0341-2040. 
Ashcroft, M., Stephens, R.M., Hallberg, B., Downward, J. & Kaplan, D.R. (1999). The 
selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in 
efficient NGF-mediated survival but defective neurite outgrowth. Oncogene, Vol.18, 
No.32, pp. 4586-4597, ISSN 0950-9232. 
Bara, I., Ozier, A., Tunon de Lara, J.M., Marthan, R. & Berger, P. (2010). Pathophysiology of 
bronchial smooth muscle remodelling in asthma. European Respiratory Journal, 
Vol.36, No.5, pp. 1174-1184, ISSN 0903-1936. 
Barbacid, M., Lamballe, F., Pulido, D. & Klein, R. (1991). The trk family of tyrosine protein 
kinase receptors. Biochimica et Biophysica Acta-Cancer Reviews, Vol.1072, No.2-3, pp. 
115-127, ISSN 1879-2561. 
Barker, P.A., Lomen-Hoerth, C., Gensch, E.M., Meakin, S.O., Glass, D.J. & Shooter, E.M. 
(1993). Tissue-specific alternative splicing generates two isoforms of the trkA 
receptor. Journal of Biological Chemistry, Vol.268, No.20, pp. 15150-15157, ISSN 0021-
9258. 
Barnes, P.J. (2010). New therapies for asthma: is there any progress? Trends in 
Pharmacological Sciences, Vol.31, No.7, pp. 335-343, ISSN 0165-6147. 
Barouch, R., Kazimirsky, G., Appel, E. & Brodie, C. (2001). Nerve growth factor regulates 
TNF-alpha production in mouse macrophages via MAP kinase activation. Journal of 
Leukocyte Biology, Vol.69, No.6, pp. 1019-1026, ISSN 0741-5400. 
Bonini, S., Lambiase, A., Bonini, S., Angelucci, F., Magrini, L., Manni, L. & Aloe, L. (1996). 
Circulating nerve growth factor levels are increased in humans with allergic 
diseases and asthma. Proceedings of the National Academy of Sciences of the United 
States of America, Vol.93, No.20, pp. 10955-10960, ISSN 0027-8424. 
Braun, A., Appel, E., Baruch, R., Herz, U., Botchkarev, V., Paus, R., Brodie, C. & Renz, H. 
(1998). Role of nerve growth factor in a mouse model of allergic airway 
inflammation and asthma. European Journal of Immunology, Vol.28, No.10, pp. 3240-
3251, ISSN 1521-4141. 
Broide, D.H., Finkelman, F., Bochner, B.S. & Rothenberg, M.E. (2011). Advances in 
mechanisms of asthma, allergy, and immunology in 2010. Journal of Allergy and 
Clinical Immunology, Vol.127, No.3, pp. 689-695, ISSN 0105-4538. 
Burgi, B., Otten, U.H., Ochensberger, B., Rihs, S., Heese, K., Ehrhard, P.B., Ibanez, C.F. & 
Dahinden, C.A. (1996). Basophil priming by neurotrophic factors. Activation 
through the trk receptor. Journal of Immunology, Vol.157, No.12, pp. 5582-5588, ISSN 
0022-1767. 
Cabrera, N., Diaz-Rodriguez, E., Becker, E., Martin-Zanca, D. & Pandiella, A. (1996). TrkA 
receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated 
fragment. Journal of Cell Biology, Vol.132, No.3, pp. 427-436, ISSN 0021-9525. 
www.intechopen.com
 
Inflammatory Diseases – A Modern Perspective 
 
90
Cantarella, G., Lempereur, L., Presta, M., Ribatti, D., Lombardo, G., Lazarovici, P., Zappala, 
G., Pafumi, C. & Bernardini, R. (2002). Nerve growth factor-endothelial cell 
interaction leads to angiogenesis in vitro and in vivo. FASEB Journal, Vol.16, No.10, 
pp. 1307-1309, ISSN 0892-6638. 
Caporali, A. & Emanueli, C. (2009). Cardiovascular actions of neurotrophins. Physiological 
Reviews, Vol.89, No.1, pp. 279-308, ISSN 0031-9333. 
Cattaneo, A. (2010). Tanezumab, a recombinant humanized mAb against nerve growth 
factor for the treatment of acute and chronic pain. Current Opinion in Molecular 
Therapeutics, Vol.12, No.1, pp. 94-106, ISSN 1464-8431. 
Chao, M.V. (2003). Neurotrophins and their receptors: a convergence point for many 
signalling pathways. Nature Reviews. Neuroscience, Vol.4, No.4, pp. 299-309, ISSN 
1471-0048. 
Chen, Z.Y., Ieraci, A., Tanowitz, M. & Lee, F.S. (2005). A novel endocytic recycling signal 
distinguishes biological responses of Trk neurotrophin receptors. Molecular Biology 
of the Cell, Vol.16, No.12, pp. 5761-5772, ISSN 1059-1524. 
Clary, D.O. & Reichardt, L.F. (1994). An alternatively spliced form of the nerve growth 
factor receptor TrkA confers an enhanced response to neurotrophin 3. Proceedings of 
the National Academy of Sciences of the United States of America, Vol.91, No.23, pp. 
11133-11137, ISSN 0027-8424. 
Coppola, V., Barrick, C.A., Southon, E.A., Celeste, A., Wang, K., Chen, B., Haddad el, B., Yin, 
J., Nussenzweig, A., Subramaniam, A. & Tessarollo, L. (2004). Ablation of TrkA 
function in the immune system causes B cell abnormalities. Development, Vol.131, 
No.20, pp. 5185-5195, ISSN 1011-6370. 
Dagnell, C., Kemi, C., Klominek, J., Eriksson, P., Skold, C.M., Eklund, A., Grunewald, J. & 
Olgart Hoglund, C. (2007). Effects of neurotrophins on human bronchial smooth 
muscle cell migration and matrix metalloproteinase-9 secretion. Translational 
Research, Vol.150, No.5, pp. 303-310, ISSN 1931-5244. 
de Vries, A., Engels, F., Henricks, P.A., Leusink-Muis, T., McGregor, G.P., Braun, A., 
Groneberg, D.A., Dessing, M.C., Nijkamp, F.P. & Fischer, A. (2006). Airway hyper-
responsiveness in allergic asthma in guinea-pigs is mediated by nerve growth 
factor via the induction of substance P: a potential role for trkA. Clinical and 
Experimental Allergy, Vol.36, No.9, pp. 1192-1200, ISSN 0954-7894. 
de Vries, A., van Rijnsoever, C., Engels, F., Henricks, P.A. & Nijkamp, F.P. (2001). The role of 
sensory nerve endings in nerve growth factor-induced airway hyperresponsiveness 
to histamine in guinea-pigs. British Journal of Pharmacology, Vol.134, No.4, pp. 771-
776, ISSN 0007-1188. 
Delcroix, J.D., Valletta, J.S., Wu, C., Hunt, S.J., Kowal, A.S. & Mobley, W.C. (2003). NGF 
signaling in sensory neurons: evidence that early endosomes carry NGF retrograde 
signals. Neuron, Vol.39, No.1, pp. 69-84, ISSN 0896-6273. 
Diaz-Rodriguez, E., Cabrera, N., Esparis-Ogando, A., Montero, J.C. & Pandiella, A. (1999). 
Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases 
generates signalling-competent truncated forms. European Journal of Neuroscience, 
Vol.11, No.4, pp. 1421-1430, ISSN 1460-9568. 
www.intechopen.com
 
Expression and Role of the TrkA Receptor in Pulmonary Inflammatory Diseases 
 
91 
Dinh, Q.T., Groneberg, D.A., Peiser, C., Springer, J., Joachim, R.A., Arck, P.C., Klapp, B.F. & 
Fischer, A. (2004). Nerve growth factor-induced substance P in capsaicin-
insensitive vagal neurons innervating the lower mouse airway. Clinical and 
Experimental Allergy, Vol.34, No.9, pp. 1474-1479, ISSN 0954-7894. 
Dolle, J.P., Rezvan, A., Allen, F.D., Lazarovici, P. & Lelkes, P.I. (2005). Nerve growth factor-
induced migration of endothelial cells. Journal of Pharmacology and Experimental 
Therapeutics, Vol.315, No.3, pp. 1220-1227, ISSN 0022-3565. 
Donovan, M.J., Miranda, R.C., Kraemer, R., McCaffrey, T.A., Tessarollo, L., Mahadeo, D., 
Sharif, S., Kaplan, D.R., Tsoulfas, P., Parada, L. & et al. (1995). Neurotrophin and 
neurotrophin receptors in vascular smooth muscle cells. Regulation of expression 
in response to injury. American Journal of Pathology, Vol.147, No.2, pp. 309-324, ISSN 
0002-9440. 
Ehrhard, P.B., Erb, P., Graumann, U. & Otten, U. (1993a). Expression of nerve growth factor 
and nerve growth factor receptor tyrosine kinase Trk in activated CD4-positive T-
cell clones. Proceedings of the National Academy of Sciences of the United States of 
America, Vol.90, No.23, pp. 10984-10988, ISSN 0027-8424. 
Ehrhard, P.B., Erb, P., Graumann, U., Schmutz, B. & Otten, U. (1994). Expression of 
functional trk tyrosine kinase receptors after T cell activation. Journal of Immunology, 
Vol.152, No.6, pp. 2705-2709, ISSN 0022-1767. 
Ehrhard, P.B., Ganter, U., Stalder, A., Bauer, J. & Otten, U. (1993b). Expression of functional 
trk protooncogene in human monocytes. Proceedings of the National Academy of 
Sciences of the United States of America, Vol.90, No.12, pp. 5423-5427, ISSN 0027-8424. 
El Zein, N., Badran, B.M. & Sariban, E. (2007). The neuropeptide pituitary adenylate cyclase 
activating protein stimulates human monocytes by transactivation of the Trk/NGF 
pathway. Cellular Signalling, Vol.19, No.1, pp. 152-162, ISSN 0898-6568. 
El Zein, N., D'Hondt, S. & Sariban, E. (2010). Crosstalks between the receptors tyrosine 
kinase EGFR and TrkA and the GPCR, FPR, in human monocytes are essential for 
receptors-mediated cell activation. Cellular Signalling, Vol.22, No.10, pp. 1437-1447, 
ISSN 0898-6568. 
Farina, A.R., Tacconelli, A., Cappabianca, L., Cea, G., Panella, S., Chioda, A., Romanelli, A., 
Pedone, C., Gulino, A. & Mackay, A.R. (2009). The alternative TrkAIII splice variant 
targets the centrosome and promotes genetic instability. Molecular and Cellular 
Biology, Vol.29, No.17, pp. 4812-4830, ISSN 0270-7306. 
Fox, A.J., Patel, H.J., Barnes, P.J. & Belvisi, M.G. (2001). Release of nerve growth factor by 
human pulmonary epithelial cells: role in airway inflammatory diseases. European 
Journal of Pharmacology, Vol.424, No.2, pp. 159-162, ISSN 0014-2999. 
Freund-Michel, V., Bertrand, C. & Frossard, N. (2006). TrkA signalling pathways in human 
airway smooth muscle cell proliferation. Cellular Signalling, Vol.18, No.5, pp. 621-
627, ISSN 0898-6568. 
Freund-Michel, V. & Frossard, N. (2008a). The nerve growth factor and its receptors in 
airway inflammatory diseases. Pharmacology and Therapeutics, Vol.117, No.1, pp. 52-
76, ISSN 0163-7258. 
www.intechopen.com
 
Inflammatory Diseases – A Modern Perspective 
 
92
Freund-Michel, V. & Frossard, N. (2008b). Overexpression of functional TrkA receptors after 
internalization in human airway smooth muscle cells. Biochimica et Biophysica Acta, 
Molecular and Cellular Research, Vol.1783, No.10, pp. 1964-1971, ISSN 0167-4889. 
Freund-Michel, V., Salagierska, M., Dubois, M., Guibert, C., Courtois, A., Marthan, R. & 
Muller, B. (2009). Potential role of the nerve growth factor NGF in pulmonary 
hypertension. European Respiratory Society annual congress, European Respiratory 
Journal, Vol.34, Suppl.53, A4330, ISSN 0903-1936, Vienna, Austria, September 2009. 
Freund-Michel, V., Laroumanie, F., Salagierska, M., Dubois, M., Courtois, A., Autissier, M., 
Guibert, C., Savineau, J.P., Marthan, R. & Muller B. (2010). Nerve growth factor 
expression and function in pulmonary arterial hypertension. European Respiratory 
Society annual congress, European Respiratory Journal, Vol.36, Suppl.54, P1080, ISSN 
0903-1936, Barcelona, Spain, September 2010. 
Freund, V., Pons, F., Joly, V., Mathieu, E., Martinet, N. & Frossard, N. (2002). Upregulation 
of nerve growth factor expression by human airway smooth muscle cells in 
inflammatory conditions. European Respiratory Journal, Vol.20, No.2, pp. 458-463, 
ISSN 0903-1936. 
Friedman, W.J. & Greene, L.A. (1999). Neurotrophin signaling via Trks and p75. 
Experimental Cell Research, Vol.253, No.1, pp. 131-142, ISSN 0014-4827. 
Frossard, N., Naline, E., Olgart Hoglund, C., Georges, O. & Advenier, C. (2005). Nerve 
growth factor is released by IL-1beta and induces hyperresponsiveness of the 
human isolated bronchus. European Respiratory Journal, Vol.26, No.1, pp. 15-20, 
ISSN 0903-1936. 
Georgieva, M.V., de Pablo, Y., Sanchis, D., Comella, J.X. & Llovera, M. (2011). Ubiquitination 
of TrkA by Nedd4-2 regulates receptor lysosomal targeting and mediates receptor 
signaling. Journal of Neurochemistry, Vol.117, No.3, pp. 479-493, ISSN 0022-3042. 
Glaab, T., Hoymann, H.G., Hecht, M., Korolewitz, R., Tschernig, T., Hohlfeld, J.M., Krug, N. 
& Braun, A. (2003). Effect of anti-nerve growth factor on early and late airway 
responses in allergic rats. Allergy, Vol.58, No.9, pp. 900-904, ISSN 0105-4538. 
Greco, A., Miranda, C., Pagliardini, S., Fusetti, L., Bongarzone, I. & Pierotti, M.A. (1997). 
Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce 
structurally different thyroid-specific TRK oncogenes. Genes, Chromosomes and 
Cancer, Vol.19, No.2, pp. 112-123, ISSN 1098-2264. 
Hahn, C., Islamian, A.P., Renz, H. & Nockher, W.A. (2006). Airway epithelial cells produce 
neurotrophins and promote the survival of eosinophils during allergic airway 
inflammation. Journal of Allergy and Clinical Immunology, Vol.117, No.4, pp. 787-794, 
ISSN 0105-4538. 
Hassoun, P.M., Mouthon, L., Barbera, J.A., Eddahibi, S., Flores, S.C., Grimminger, F., Jones, 
P.L., Maitland, M.L., Michelakis, E.D., Morrell, N.W., Newman, J.H., Rabinovitch, 
M., Schermuly, R., Stenmark, K.R., Voelkel, N.F., Yuan, J.X. & Humbert, M. (2009). 
Inflammation, growth factors, and pulmonary vascular remodeling. Journal of the 
American College of Cardiology, Vol.54, No.1 Suppl, pp. S10-19, ISSN 0735-1097. 
Heerssen, H.M. & Segal, R.A. (2002). Location, location, location: a spatial view of 
neurotrophin signal transduction. Trends in Neurosciences, Vol.25, No.3, pp. 160-165, 
ISSN 0166-2236. 
www.intechopen.com
 
Expression and Role of the TrkA Receptor in Pulmonary Inflammatory Diseases 
 
93 
Hefti, F.F., Rosenthal, A., Walicke, P.A., Wyatt, S., Vergara, G., Shelton, D.L. & Davies, A.M. 
(2006). Novel class of pain drugs based on antagonism of NGF. Trends in 
Pharmacological Sciences, Vol.27, No.2, pp. 85-91, ISSN 0165-6147. 
Hikawa, S., Kobayashi, H., Hikawa, N., Kusakabe, T., Hiruma, H., Takenaka, T., Tomita, T. 
& Kawakami, T. (2002). Expression of neurotrophins and their receptors in 
peripheral lung cells of mice. Histochemistry and Cell Biology, Vol.118, No.1, pp. 51-
58, ISSN 0948-6143. 
Holgado-Madruga, M., Moscatello, D.K., Emlet, D.R., Dieterich, R. & Wong, A.J. (1997). 
Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the 
promotion of cell survival by nerve growth factor. Proceedings of the National 
Academy of Sciences of the United States of America, Vol.94, No.23, pp. 12419-12424, 
ISSN 0027-8424. 
Hoyle, G.W., Graham, R.M., Finkelstein, J.B., Nguyen, K.P., Gozal, D. & Friedman, M. 
(1998). Hyperinnervation of the airways in transgenic mice overexpressing nerve 
growth factor. American Journal of Respiratory Cell and Molecular Biology, Vol.18, 
No.2, pp. 149-157, ISSN 1044-1549. 
Humbert, M. (2010). Pulmonary arterial hypertension and chronic thromboembolic 
pulmonary hypertension: pathophysiology. European Respiratory Review, Vol.19, 
No.115, pp. 59-63, ISSN 0905-9180. 
Humbert, M., Morrell, N.W., Archer, S.L., Stenmark, K.R., MacLean, M.R., Lang, I.M., 
Christman, B.W., Weir, E.K., Eickelberg, O., Voelkel, N.F. & Rabinovitch, M. (2004). 
Cellular and molecular pathobiology of pulmonary arterial hypertension. Journal of 
the American College of Cardiology, Vol.43, No.12 Suppl S, pp. 13S-24S, ISSN 0735-
1097. 
Indo, Y., Mardy, S., Tsuruta, M., Karim, M.A. & Matsuda, I. (1997). Structure and 
organization of the human TRKA gene encoding a high affinity receptor for nerve 
growth factor. Japanese Journal of Human Genetics, Vol.42, No.2, pp. 343-351, ISSN 
0916-8478. 
Jullien, J., Guili, V., Reichardt, L.F. & Rudkin, B.B. (2002). Molecular kinetics of nerve growth 
factor receptor trafficking and activation. Journal of Biological Chemistry, Vol.277, 
No.41, pp. 38700-38708, ISSN 0021-9258. 
Kaplan, D.R., Hempstead, B.L., Martin-Zanca, D., Chao, M.V. & Parada, L.F. (1991a). The trk 
proto-oncogene product: a signal transducing receptor for nerve growth factor. 
Science, Vol.252, No.5005, pp. 554-558, ISSN 0036-8075. 
Kaplan, D.R., Martin-Zanca, D. & Parada, L.F. (1991b). Tyrosine phosphorylation and 
tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature, 
Vol.350, No.6314, pp. 158-160, ISSN 0028-0836. 
Kassel, O., de Blay, F., Duvernelle, C., Olgart, C., Israel-Biet, D., Krieger, P., Moreau, L., 
Muller, C., Pauli, G. & Frossard, N. (2001). Local increase in the number of mast 
cells and expression of nerve growth factor in the bronchus of asthmatic patients 
after repeated inhalation of allergen at low-dose. Clinical and Experimental Allergy, 
Vol.31, No.9, pp. 1432-1440, ISSN 0954-7894. 
Kawamoto, K., Aoki, J., Tanaka, A., Itakura, A., Hosono, H., Arai, H., Kiso, Y. & Matsuda, H. 
(2002). Nerve growth factor activates mast cells through the collaborative 
www.intechopen.com
 
Inflammatory Diseases – A Modern Perspective 
 
94
interaction with lysophosphatidylserine expressed on the membrane surface of 
activated platelets. Journal of Immunology, Vol.168, No.12, pp. 6412-6419, ISSN 0022-
1767. 
Kawamoto, K., Okada, T., Kannan, Y., Ushio, H., Matsumoto, M. & Matsuda, H. (1995). 
Nerve growth factor prevents apoptosis of rat peritoneal mast cells through the trk 
proto-oncogene receptor. Blood, Vol.86, No.12, pp. 4638-4644, ISSN 0006-4971. 
Khan, K.M., Falcone, D.J. & Kraemer, R. (2002). Nerve growth factor activation of Erk-1 and 
Erk-2 induces matrix metalloproteinase-9 expression in vascular smooth muscle 
cells. Journal of Biological Chemistry, Vol.277, No.3, pp. 2353-2359, ISSN 0021-9258. 
Kim, J.Y., Kim, D.Y. & Ro, J.Y. (2008). Granule formation in NGF-cultured mast cells is 
associated with expressions of pyruvate kinase type M2 and annexin I proteins. 
International Archives of Allergy and Immunology, Vol.146, No.4, pp. 287-297, ISSN 
1018-2438. 
Kita, Y., Kimura, K.D., Kobayashi, M., Ihara, S., Kaibuchi, K., Kuroda, S., Ui, M., Iba, H., 
Konishi, H., Kikkawa, U., Nagata, S. & Fukui, Y. (1998). Microinjection of activated 
phosphatidylinositol-3 kinase induces process outgrowth in rat PC12 cells through 
the Rac-JNK signal transduction pathway. Journal of Cell Science, Vol.111 ( Pt 7), pp. 
907-915, ISSN 0021-9533. 
Klein, R., Jing, S.Q., Nanduri, V., O'Rourke, E. & Barbacid, M. (1991). The trk proto-
oncogene encodes a receptor for nerve growth factor. Cell, Vol.65, No.1, pp. 189-
197, ISSN 0092-8674. 
Kohyama, T., Liu, X., Wen, F.Q., Kobayashi, T., Abe, S., Ertl, R. & Rennard, S.I. (2002). Nerve 
growth factor stimulates fibronectin-induced fibroblast migration. Journal of 
Laboratory and Clinical Medicine, Vol.140, No.5, pp. 329-335, ISSN 0022-2143. 
Korhonen, J.M., Said, F.A., Wong, A.J. & Kaplan, D.R. (1999). Gab1 mediates neurite 
outgrowth, DNA synthesis, and survival in PC12 cells. Journal of Biological 
Chemistry, Vol.274, No.52, pp. 37307-37314, ISSN 0021-9258. 
Kraemer, R., Nguyen, H., March, K.L. & Hempstead, B. (1999). NGF activates similar 
intracellular signaling pathways in vascular smooth muscle cells as PDGF-BB but 
elicits different biological responses. Arteriosclerosis, Thrombosis, and Vascular 
Biology, Vol.19, No.4, pp. 1041-1050, ISSN 1079-5642. 
Kronfeld, I., Kazimirsky, G., Gelfand, E.W. & Brodie, C. (2002). NGF rescues human B 
lymphocytes from anti-IgM induced apoptosis by activation of PKCzeta. European 
Journal of Immunology, Vol.32, No.1, pp. 136-143, ISSN 1521-4141. 
Kuruvilla, R., Ye, H. & Ginty, D.D. (2000). Spatially and functionally distinct roles of the PI3-
K effector pathway during NGF signaling in sympathetic neurons. Neuron, Vol.27, 
No.3, pp. 499-512, ISSN 0896-6273. 
la Sala, A., Corinti, S., Federici, M., Saragovi, H.U. & Girolomoni, G. (2000). Ligand 
activation of nerve growth factor receptor TrkA protects monocytes from apoptosis. 
Journal of Leukocyte Biology, Vol.68, No.1, pp. 104-110, ISSN 0741-5400. 
Lambiase, A., Bracci-Laudiero, L., Bonini, S., Bonini, S., Starace, G., D'Elios, M.M., De Carli, 
M. & Aloe, L. (1997). Human CD4+ T cell clones produce and release nerve growth 
factor and express high-affinity nerve growth factor receptors. Journal of Allergy and 
Clinical Immunology, Vol.100, No.3, pp. 408-414, ISSN 0105-4538. 
www.intechopen.com
 
Expression and Role of the TrkA Receptor in Pulmonary Inflammatory Diseases 
 
95 
Lane, N.E., Schnitzer, T.J., Birbara, C.A., Mokhtarani, M., Shelton, D.L., Smith, M.D. & 
Brown, M.T. (2010). Tanezumab for the treatment of pain from osteoarthritis of the 
knee. New England Journal of Medicine, Vol.363, No.16, pp. 1521-1531, ISSN 0028-
4793. 
Lecht, S., Arien-Zakay, H., Wagenstein, Y., Inoue, S., Marcinkiewicz, C., Lelkes, P.I. & 
Lazarovici, P. (2010) Transient signaling of Erk1/2, Akt and PLCgamma induced 
by nerve growth factor in brain capillary endothelial cells. Vascular Pharmacology, 
Vol.53, No.3-4, pp. 107-114, ISSN 1537-1891. 
Lee, F.S. & Chao, M.V. (2001). Activation of Trk neurotrophin receptors in the absence of 
neurotrophins. Proceedings of the National Academy of Sciences of the United States of 
America, Vol.98, No.6, pp. 3555-3560, ISSN 0027-8424. 
Lee, F.S., Rajagopal, R. & Chao, M.V. (2002a). Distinctive features of Trk neurotrophin 
receptor transactivation by G protein-coupled receptors. Cytokine and Growth Factor 
Reviews, Vol.13, No.1, pp. 11-17, ISSN 1359-6101. 
Lee, F.S., Rajagopal, R., Kim, A.H., Chang, P.C. & Chao, M.V. (2002b). Activation of Trk 
neurotrophin receptor signaling by pituitary adenylate cyclase-activating 
polypeptides. Journal of Biological Chemistry, Vol.277, No.11, pp. 9096-9102, ISSN 
0021-9258. 
Leon, A., Buriani, A., Dal Toso, R., Fabris, M., Romanello, S., Aloe, L. & Levi-Montalcini, R. 
(1994). Mast cells synthesize, store, and release nerve growth factor. Proceedings of 
the National Academy of Sciences of the United States of America, Vol.91, No.9, pp. 3739-
3743, ISSN 0027-8424. 
Levi-Montalcini, R., Dal Toso, R., della Valle, F., Skaper, S.D. & Leon, A. (1995). Update of 
the NGF saga. Journal of the Neurological Sciences, Vol.130, No.2, pp. 119-127, ISSN 
0022-510X. 
Levi-Montalcini, R. & Hamburger, V. (1951). Selective growth stimulating effects of mouse 
sarcoma on the sensory and sympathetic nervous system of the chick embryo. 
Journal of Experimental Zoology, Vol.116, No.2, pp. 321-361, ISSN 0022-104X. 
Li, L., Kong, L., Fang, X., Jiang, C., Wang, Y., Zhong, Z., Sun, Q., Gu, G., Zheng, D., Meng, R. 
& Kang, J. (2009). SH2-B beta expression in alveolar macrophages in BAL fluid of 
asthmatic guinea pigs and its role in NGF-TrkA-mediated asthma. Respirology, 
Vol.14, No.1, pp. 60-68, 1323-7799. 
Lomen-Hoerth, C. & Shooter, E.M. (1995). Widespread neurotrophin receptor expression in 
the immune system and other nonneuronal rat tissues. Journal of Neurochemistry, 
Vol.64, No.4, pp. 1780-1789, ISSN 0022-3042. 
Ma, W.Y., Murata, E., Ueda, K., Kuroda, Y., Cao, M.H., Abe, M., Shigemi, K. & Hirose, M. 
(2010). A synthetic cell-penetrating peptide antagonizing TrkA function suppresses 
neuropathic pain in mice. Journal of Pharmacological Sciences, Vol.114, No.1, pp. 79-
84, ISSN 0022-3549. 
Martin-Zanca, D., Mitra, G., Long, L.K. & Barbacid, M. (1986). Molecular characterization of 
the human trk oncogene. Cold Spring Harbor Symposia on Quantitative Biology, Vol.51 
Pt 2, pp. 983-992, ISSN 0091-7451. 
www.intechopen.com
 
Inflammatory Diseases – A Modern Perspective 
 
96
Martin, K.J., Shpiro, N., Traynor, R., Elliott, M. & Arthur, J.S. (2011). Comparison of the 
specificity of Trk inhibitors in recombinant and neuronal assays. 
Neuropharmacology, Vol.61, No.1-2, pp. 148-155, ISSN 1570-159X. 
McNamee, K.E., Burleigh, A., Gompels, L.L., Feldmann, M., Allen, S.J., Williams, R.O., 
Dawbarn, D., Vincent, T.L. & Inglis, J.J. (2010). Treatment of murine osteoarthritis 
with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory 
joint pain. Pain, Vol.149, No.2, pp. 386-392, ISSN 0304-3959. 
Meakin, S.O. & Shooter, E.M. (1992). The nerve growth factor family of receptors. Trends in 
Neurosciences, Vol.15, No.9, pp. 323-331, ISSN 0166-2236. 
Melamed, I., Kelleher, C.A., Franklin, R.A., Brodie, C., Hempstead, B., Kaplan, D. & Gelfand, 
E.W. (1996). Nerve growth factor signal transduction in human B lymphocytes is 
mediated by gp140trk. European Journal of Immunology, Vol.26, No.9, pp. 1985-1992, 
ISSN 1521-4141. 
Metsis, M. (2001). Genes for neurotrophic factors and their receptors: structure and 
regulation. Cellular and Molecular Life Sciences, Vol.58, No.8, pp. 1014-1020, ISSN 
1420-682X. 
Meuchel, L.W., Thompson, M.A., Cassivi, S.D., Pabelick, C.M. & Prakash, Y.S. (2011). 
Neurotrophins induce nitric oxide generation in human pulmonary artery 
endothelial cells. Cardiovascular Research, 2011 May 18, [Epub ahead of print], ISSN 
0008-6363. 
Micera, A., Vigneti, E., Pickholtz, D., Reich, R., Pappo, O., Bonini, S., Maquart, F.X., Aloe, L. 
& Levi-Schaffer, F. (2001). Nerve growth factor displays stimulatory effects on 
human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue 
repair. Proceedings of the National Academy of Sciences of the United States of America, 
Vol.98, No.11, pp. 6162-6167, ISSN 0027-8424. 
Mitra, G. (1991). Mutational analysis of conserved residues in the tyrosine kinase domain of 
the human trk oncogene. Oncogene, Vol.6, No.12, pp. 2237-2241, ISSN 0950-9232. 
Nakamura, K., Tan, F., Li, Z. & Thiele, C.J. (2011). NGF activation of TrkA induces vascular 
endothelial growth factor expression via induction of hypoxia-inducible factor-
1alpha. Molecular and Cellular Neurosciences, Vol.46, No.2, pp. 498-506, ISSN 1044-
7431. 
Nassenstein, C., Braun, A., Erpenbeck, V.J., Lommatzsch, M., Schmidt, S., Krug, N., 
Luttmann, W., Renz, H. & Virchow, J.C., Jr. (2003). The neurotrophins nerve growth 
factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 are 
survival and activation factors for eosinophils in patients with allergic bronchial 
asthma. Journal of Experimental Medicine, Vol.198, No.3, pp. 455-467, ISSN 0022-1007. 
Nassenstein, C., Dawbarn, D., Pollock, K., Allen, S.J., Erpenbeck, V.J., Spies, E., Krug, N. & 
Braun, A. (2006). Pulmonary distribution, regulation, and functional role of Trk 
receptors in a murine model of asthma. Journal of Allergy and Clinical Immunology, 
Vol.118, No.3, pp. 597-605, ISSN 0105-4538. 
Ni, X., Li, X., Fang, X., Li, N., Cui, W. & Zhang, B. (2010). NGF/TrkA-mediated 
Kidins220/ARMS signaling activated in the allergic airway challenge in mice. 
Annals of Allergy, Asthma, and Immunology, Vol.105, No.4, pp. 299-306, ISSN 1081-
1206. 
www.intechopen.com
 
Expression and Role of the TrkA Receptor in Pulmonary Inflammatory Diseases 
 
97 
Noga, O., Englmann, C., Hanf, G., Grutzkau, A., Guhl, S. & Kunkel, G. (2002). Activation of 
the specific neurotrophin receptors TrkA, TrkB and TrkC influences the function of 
eosinophils. Clinical and Experimental Allergy, Vol.32, No.9, pp. 1348-1354, ISSN 
0954-7894. 
Obermeier, A., Halfter, H., Wiesmuller, K.H., Jung, G., Schlessinger, J. & Ullrich, A. (1993). 
Tyrosine 785 is a major determinant of Trk-substrate interaction. EMBO Journal, 
Vol.12, No.3, pp. 933-941, ISSN 0261-4189. 
Olgart, C. & Frossard, N. (2001). Human lung fibroblasts secrete nerve growth factor: effect 
of inflammatory cytokines and glucocorticoids. European Respiratory Journal, Vol.18, 
No.1, pp. 115-121, ISSN 0903-1936. 
Olgart Hoglund, C., de Blay, F., Oster, J.P., Duvernelle, C., Kassel, O., Pauli, G. & Frossard, 
N. (2002). Nerve growth factor levels and localisation in human asthmatic bronchi. 
European Respiratory Journal, Vol.20, No.5, pp. 1110-1116, ISSN 0903-1936. 
Othumpangat, S., Gibson, L.F., Samsell, L. & Piedimonte, G. (2009). NGF is an essential 
survival factor for bronchial epithelial cells during respiratory syncytial virus 
infection. PLoS ONE, Vol.4, No.7, pp. e6444, ISSN 1932-6203. 
Otten, U., Scully, J.L., Ehrhard, P.B. & Gadient, R.A. (1994). Neurotrophins: signals between 
the nervous and immune systems. Progress in Brain Research, Vol.103, pp. 293-305, 
ISSN 0079-6123. 
Patapoutian, A. & Reichardt, L.F. (2001). Trk receptors: mediators of neurotrophin action. 
Current Opinion in Neurobiology, Vol.11, No.3, pp. 272-280, ISSN 0959-4388. 
Path, G., Braun, A., Meents, N., Kerzel, S., Quarcoo, D., Raap, U., Hoyle, G.W., Nockher, 
W.A. & Renz, H. (2002). Augmentation of allergic early-phase reaction by nerve 
growth factor. American Journal of Respiratory and Critical Care Medicine, Vol.166, 
No.6, pp. 818-826, ISSN 073-449X. 
Philippidou, P., Valdez, G., Akmentin, W., Bowers, W.J., Federoff, H.J. & Halegoua, S. 
(2011). Trk retrograde signaling requires persistent, Pincher-directed endosomes. 
Proceedings of the National Academy of Sciences of the United States of America, Vol.108, 
No.2, pp. 852-857, ISSN 0027-8424. 
Pons, F., Freund, V., Kuissu, H., Mathieu, E., Olgart, C. & Frossard, N. (2001). Nerve growth 
factor secretion by human lung epithelial A549 cells in pro- and anti-inflammatory 
conditions. European Journal of Pharmacology, Vol.428, No.3, pp. 365-369, ISSN 0014-
2999. 
Prakash, Y., Thompson, M.A., Meuchel, L., Pabelick, C.M., Mantilla, C.B., Zaidi, S. & Martin, 
R.J. (2010). Neurotrophins in lung health and disease. Expert Review of Respiratory 
Medicine, Vol.4, No.3, pp. 395-411, ISSN 1747-6348. 
Quarcoo, D., Schulte-Herbruggen, O., Lommatzsch, M., Schierhorn, K., Hoyle, G.W., Renz, 
H. & Braun, A. (2004). Nerve growth factor induces increased airway inflammation 
via a neuropeptide-dependent mechanism in a transgenic animal model of allergic 
airway inflammation. Clinical and Experimental Allergy, Vol.34, No.7, pp. 1146-1151, 
ISSN 0954-7894. 
Rahbek, U.L., Dissing, S., Thomassen, C., Hansen, A.J. & Tritsaris, K. (2005). Nerve growth 
factor activates aorta endothelial cells causing PI3K/Akt- and ERK-dependent 
www.intechopen.com
 
Inflammatory Diseases – A Modern Perspective 
 
98
migration. Pflugers Archiv (European Journal of Physiology), Vol.450, No.5, pp. 355-
361, ISSN 0031-6768. 
Rajagopal, R., Chen, Z.Y., Lee, F.S. & Chao, M.V. (2004). Transactivation of Trk neurotrophin 
receptors by G-protein-coupled receptor ligands occurs on intracellular 
membranes. Journal of Neuroscience, Vol.24, No.30, pp. 6650-6658, ISSN 0270-6474. 
Ricci, A., Bronzetti, E., Mannino, F., Felici, L., Terzano, C. & Mariotta, S. (2004a). Elevated 
neurotrophin and neurotrophin receptor expression in spontaneously hypertensive 
rat lungs. Growth Factors, Vol.22, No.3, pp. 195-205, ISSN 0897-7194. 
Ricci, A., Felici, L., Mariotta, S., Mannino, F., Schmid, G., Terzano, C., Cardillo, G., Amenta, 
F. & Bronzetti, E. (2004b). Neurotrophin and neurotrophin receptor protein 
expression in the human lung. American Journal of Respiratory Cell and Molecular 
Biology, Vol.30, No.1, pp. 12-19, ISSN 1044-1549. 
Ricci, A., Greco, S., Amenta, F., Bronzetti, E., Felici, L., Rossodivita, I., Sabbatini, M. & 
Mariotta, S. (2000a). Neurotrophins and neurotrophin receptors in human 
pulmonary arteries. Journal of Vascular Research, Vol.37, No.5, pp. 355-363, ISSN 
1018-1172. 
Ricci, A., Greco, S., Mariotta, S., Felici, L., Amenta, F. & Bronzetti, E. (2000b). Neurotrophin 
and neurotrophin receptor expression in alveolar macrophages: an 
immunocytochemical study. Growth Factors, Vol.18, No.3, pp. 193-202, ISSN 0897-
7194. 
Ryden, M. & Ibanez, C.F. (1996). Binding of neurotrophin-3 to p75LNGFR, TrkA, and TrkB 
mediated by a single functional epitope distinct from that recognized by trkC. 
Journal of Biological Chemistry, Vol.271, No.10, pp. 5623-5627, ISSN 0021-9258. 
Sawada, J., Itakura, A., Tanaka, A., Furusaka, T. & Matsuda, H. (2000). Nerve growth factor 
functions as a chemoattractant for mast cells through both mitogen-activated 
protein kinase and phosphatidylinositol 3-kinase signaling pathways. Blood, Vol.95, 
No.6, pp. 2052-2058, ISSN 0006-4971. 
Saxena, S., Howe, C.L., Cosgaya, J.M., Steiner, P., Hirling, H., Chan, J.R., Weis, J. & Kruttgen, 
A. (2005). Differential endocytic sorting of p75NTR and TrkA in response to NGF: a 
role for late endosomes in TrkA trafficking. Molecular and Cellular Neurosciences, 
Vol.28, No.3, pp. 571-587, ISSN 1044-7431. 
Segal, R.A. & Greenberg, M.E. (1996). Intracellular signaling pathways activated by 
neurotrophic factors. Annual Review of Neuroscience, Vol.19, pp. 463-489, ISSN 0743-
4634. 
Sherer, T.B., Neff, P.S., Hankins, G.R. & Tuttle, J.B. (1998). Mechanisms of increased NGF 
production in vascular smooth muscle of the spontaneously hypertensive rat. 
Experimental Cell Research, Vol.241, No.1, pp. 186-193, ISSN 0014-4827. 
Sin, A.Z., Roche, E.M., Togias, A., Lichtenstein, L.M. & Schroeder, J.T. (2001). Nerve growth 
factor or IL-3 induces more IL-13 production from basophils of allergic subjects 
than from basophils of nonallergic subjects. Journal of Allergy and Clinical 
Immunology, Vol.108, No.3, pp. 387-393, ISSN 0105-4538. 
Skaper, S.D. (2008). The biology of neurotrophins, signalling pathways, and functional 
peptide mimetics of neurotrophins and their receptors. CNS and Neurological 
Disorders Drug Targets, Vol.7, No.1, pp. 46-62, ISSN 1871-5273. 
www.intechopen.com
 
Expression and Role of the TrkA Receptor in Pulmonary Inflammatory Diseases 
 
99 
Solomon, A., Aloe, L., Pe'er, J., Frucht-Pery, J., Bonini, S., Bonini, S. & Levi-Schaffer, F. 
(1998). Nerve growth factor is preformed in and activates human peripheral blood 
eosinophils. Journal of Allergy and Clinical Immunology, Vol.102, No.3, pp. 454-460, 
ISSN 0105-4538. 
Stephens, R.M., Loeb, D.M., Copeland, T.D., Pawson, T., Greene, L.A. & Kaplan, D.R. (1994). 
Trk receptors use redundant signal transduction pathways involving SHC and 
PLC-gamma 1 to mediate NGF responses. Neuron, Vol.12, No.3, pp. 691-705, ISSN 
0896-6273. 
Susaki, Y., Shimizu, S., Katakura, K., Watanabe, N., Kawamoto, K., Matsumoto, M., 
Tsudzuki, M., Furusaka, T., Kitamura, Y. & Matsuda, H. (1996). Functional 
properties of murine macrophages promoted by nerve growth factor. Blood, Vol.88, 
No.12, pp. 4630-4637, ISSN 0006-4971. 
Tacconelli, A., Farina, A.R., Cappabianca, L., Gulino, A. & Mackay, A.R. (2005). TrkAIII. A 
novel hypoxia-regulated alternative TrkA splice variant of potential physiological 
and pathological importance. Cell Cycle, Vol.4, No.1, pp. 8-9, ISSN 1538-4101. 
Takahashi, H., Uno, S., Watanabe, Y., Arakawa, K. & Nakagawa, S. (2000). Expression of 
nerve growth factor-induced type 1 plasminogen activator inhibitor (PAI-1) mRNA 
is inhibited by genistein and wortmannin. Neuroreport, Vol.11, No.5, pp. 1111-1115, 
ISSN 0959-4965. 
Takahashi, Y., Shimokawa, N., Esmaeili-Mahani, S., Morita, A., Masuda, H., Iwasaki, T., 
Tamura, J., Haglund, K. & Koibuchi, N. (2011). Ligand-induced downregulation of 
TrkA is partly regulated through ubiquitination by Cbl. FEBS Letters, Vol.585, 
No.12, pp. 1741-1747, ISSN 0014-5793. 
Tam, S.Y., Tsai, M., Yamaguchi, M., Yano, K., Butterfield, J.H. & Galli, S.J. (1997). Expression 
of functional TrkA receptor tyrosine kinase in the HMC-1 human mast cell line and 
in human mast cells. Blood, Vol.90, No.5, pp. 1807-1820, ISSN 0006-4971. 
Torcia, M., Bracci-Laudiero, L., Lucibello, M., Nencioni, L., Labardi, D., Rubartelli, A., 
Cozzolino, F., Aloe, L. & Garaci, E. (1996). Nerve growth factor is an autocrine 
survival factor for memory B lymphocytes. Cell, Vol.85, No.3, pp. 345-356, ISSN 
0092-8674. 
Ueda, K., Hirose, M., Murata, E., Takatori, M., Ueda, M., Ikeda, H. & Shigemi, K. (2010). 
Local administration of a synthetic cell-penetrating peptide antagonizing TrkA 
function suppresses inflammatory pain in rats. Journal of Pharmacological Sciences, 
Vol.112, No.4, pp. 438-443, ISSN 0022-3549. 
Watson, J.J., Allen, S.J. & Dawbarn, D. (2008). Targeting nerve growth factor in pain: what is 
the therapeutic potential? BioDrugs, Vol.22, No.6, pp. 349-359, ISSN 1173-8804. 
Weier, H.U., Rhein, A.P., Shadravan, F., Collins, C. & Polikoff, D. (1995). Rapid physical 
mapping of the human trk protooncogene (NTRK1) to human chromosome 1q21-
q22 by P1 clone selection, fluorescence in situ hybridization (FISH), and computer-
assisted microscopy. Genomics, Vol.26, No.2, pp. 390-393, ISSN 0888-7543. 
Wiese, S., Digby, M.R., Gunnersen, J.M., Gotz, R., Pei, G., Holtmann, B., Lowenthal, J. & 
Sendtner, M. (1999). The anti-apoptotic protein ITA is essential for NGF-mediated 
survival of embryonic chick neurons. Nature Neuroscience, Vol.2, No.11, pp. 978-983, 
ISSN 1097-6256. 
www.intechopen.com
 
Inflammatory Diseases – A Modern Perspective 
 
100 
Wiesmann, C. & de Vos, A.M. (2001). Nerve growth factor: structure and function. Cellular 
and Molecular Life Sciences, Vol.58, No.5-6, pp. 748-759, ISSN 1420-682X. 
Wilfong, E.R. & Dey, R.D. (2004). Nerve growth factor and substance P regulation in nasal 
sensory neurons after toluene diisocyanate exposure. American Journal of Respiratory 
Cell and Molecular Biology, Vol.30, No.6, pp. 793-800, ISSN 1044-1549. 
Wilfong, E.R. & Dey, R.D. (2005). The release of nerve growth factor from the nasal mucosa 
following toluene diisocyanate. Journal of Toxicology and Environmental Health. Part 
A, Vol.68, No.15, pp. 1337-1348, ISSN 1528-7394. 
Wooten, M.W., Zhou, G., Seibenhener, M.L. & Coleman, E.S. (1994). A role for zeta protein 
kinase C in nerve growth factor-induced differentiation of PC12 cells. Cell Growth 
and Differentiation, Vol.5, No.4, pp. 395-403, ISSN 1044-9523. 
Wu, Z.X. & Dey, R.D. (2006). Nerve growth factor-enhanced airway responsiveness involves 
substance P in ferret intrinsic airway neurons. American Journal of Physiology. Lung 
Cellular and Molecular Physiology, Vol.291, No.1, pp. L111-118, ISSN 1040-0605. 
Xu, M., Remillard, C.V., Sachs, B.D., Makino, A., Platoshyn, O., Yao, W., Dillmann, W.H., 
Akassoglou, K. & Yuan, J.X. (2008). p75 neurotrophin receptor regulates agonist-
induced pulmonary vasoconstriction. American Journal of Physiology. Heart and 
Circulatory Physiology, Vol.295, No.4, pp. H1529-1538, ISSN 0363-6135. 
Yamaguchi, Y., Katoh, H., Yasui, H., Mori, K. & Negishi, M. (2001). RhoA inhibits the nerve 
growth factor-induced Rac1 activation through Rho-associated kinase-dependent 
pathway. Journal of Biological Chemistry, Vol.276, No.22, pp. 18977-18983, ISSN 0021-
9258. 
York, R.D., Molliver, D.C., Grewal, S.S., Stenberg, P.E., McCleskey, E.W. & Stork, P.J. (2000). 
Role of phosphoinositide 3-kinase and endocytosis in nerve growth factor-induced 
extracellular signal-regulated kinase activation via Ras and Rap1. Molecular and 
Cellular Biology, Vol.20, No.21, pp. 8069-8083, ISSN 0270-7306. 
Zweifel, L.S., Kuruvilla, R. & Ginty, D.D. (2005). Functions and mechanisms of retrograde 
neurotrophin signalling. Nature Reviews. Neuroscience, Vol.6, No.8, pp. 615-625, 
ISSN 1471-0048. 
www.intechopen.com
Inflammatory Diseases - A Modern Perspective
Edited by Dr. Amit Nagal
ISBN 978-953-307-444-3
Hard cover, 240 pages
Publisher InTech
Published online 16, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
"Inflammatory Diseases - A Modern Perspective" represents an extended and thoroughly revised collection of
papers on inflammation. This book explores a wide range of topics relevant to inflammation and inflammatory
diseases while its main objective is to help in understanding the molecular mechanism and a concrete review
of inflammation. One of the interesting things about this book is its diversity in topics which include
pharmacology, medicine, rational drug design, microbiology and biochemistry. Each topic focuses on
inflammation and its related disease thus giving a unique platform which integrates all the useful information
regarding inflammation.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ve ́ronique Freund-Michel, Bernard Muller and Nelly Frossard (2011). Expression and Role of the TrkA
Receptor in Pulmonary Inflammatory Diseases, Inflammatory Diseases - A Modern Perspective, Dr. Amit Nagal
(Ed.), ISBN: 978-953-307-444-3, InTech, Available from: http://www.intechopen.com/books/inflammatory-
diseases-a-modern-perspective/expression-and-role-of-the-trka-receptor-in-pulmonary-inflammatory-diseases
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
